Cai Luo-Yang, Yuan Ying, Huang Hai, Zhang Jin, Zou Xin-Yi, Zhang Xiao-Ming
School of Acupuncture-Moxibustion and Orthopedics, Hubei University of Chinese Medicine, Wuhan, China.
Hubei Shizhen Laboratory, Wuhan, China.
Front Neurosci. 2025 Mar 20;19:1536055. doi: 10.3389/fnins.2025.1536055. eCollection 2025.
Cerebral ischemia-reperfusion injury (CIRI) is a complex pathophysiological process faced by brain tissues after ischemic stroke treatment, which involves mechanisms of inflammatory response, oxidative stress and apoptosis, and severely affects treatment outcome. Lipocalin-2 (LCN2), an acute-phase protein, is significantly up-regulated after CIRI and promotes neural repair by enhancing astrocyte phagocytosis, but its over-activation may also trigger secondary inflammation and demyelination injury. LCN2 also plays a key role in neuroinflammation regulation by regulating the polarization state of astrocytes and the release of inflammatory factors, and may affect the integrity of the blood-brain barrier and a variety of pathologic injury processes. In view of the important role of LCN2 in CIRI, this article reviews the mechanism of LCN2, aiming to provide new ideas and methods for the treatment of ischemic stroke.
脑缺血再灌注损伤(CIRI)是缺血性脑卒中治疗后脑组织面临的一个复杂病理生理过程,它涉及炎症反应、氧化应激和细胞凋亡机制,严重影响治疗效果。脂质运载蛋白-2(LCN2)是一种急性期蛋白,在CIRI后显著上调,并通过增强星形胶质细胞吞噬作用促进神经修复,但其过度激活也可能引发继发性炎症和脱髓鞘损伤。LCN2还通过调节星形胶质细胞的极化状态和炎症因子的释放,在神经炎症调节中起关键作用,并可能影响血脑屏障的完整性和多种病理损伤过程。鉴于LCN2在CIRI中的重要作用,本文综述了LCN2的作用机制,旨在为缺血性脑卒中的治疗提供新思路和方法。